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SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma 
Destructive bone lesions due to osteolytic bone disease (OBD) are a major cause of morbidity and 
mortality in multiple myeloma (MM) patients and the development of new therapeutic strategies is of 
great interest. In this study, we assessed the effect of SRC inhibition with saracatinib (AZD0530, 
AstraZeneca) on the development of MM and its associated OBD.  
We first determined SRC family kinase expression in the multiple myeloma microenvironment and found 
that patient-derived MM cells express SRC at low levels and disease stage does not correlate with SRC 
expression levels. SRC expression was found to increase during osteoclast differentiation and decrease 
during osteoblast differentiation. Next, we validated an inhibitory role of saracatinib on osteoclast 
differentiation and function. Saracatinib inhibited the differentiation and polarization of RAW264.7 
osteoclasts, reflected by a decrease of CTSK and DC-STAMP levels and a defective actin ring formation 
and culminating in a complete inhibition of bone matrix resorption. In addition, we found that 
saracatinib inhibits collagen secretion by MC3T3-E1 osteoblasts. 
In vivo, saracatinib did not alter MM bone marrow plasmocytosis in both the 5TGM.1 and 5T2MM 
murine myeloma models. However, bone destruction was markedly reduced in both models following 
treatment with saracatinib. In the 5TGM.1 model multiple trabecular bone parameters were restored to 
levels observed in healthy control mice following saracatinib treatment, including BV/TV, Tb.N. and 
Tb.Th.. These results were confirmed in the 5T2MM model, which displays a more severe osteolytic 
bone disease. In addition, saracatinib treatment resulted in an increase in cortical thickness and a 
decrease in the number and size of cortical lesions in 5TGM.1 mice. These findings were corroborated by 
histomorphometric analyses.  
In conclusion, we report a potent inhibitory preclinical effect of the SRC inhibitor saracatinib on the 
development of OBD in MM. Our results indicate that saracatinib exerts this effect via blocking of 
osteoclast function. These findings warrant further study of the feasibility and efficacy of saracatinib to 
treat OBD in MM patients.  
 
